Literature DB >> 6906229

The binding of human complement component C4 to antibody-antigen aggregates.

R D Campbell, A W Dodds, R R Porter.   

Abstract

The binding of human complement component C4 to antibody-antigen aggregates and the nature of the interaction have been investigated. When antibody-antigen aggregates with optimal C1 bound are incubated with C4, the C4 is rapidly cleaved to C4b, but only a small fraction (1-2%) is bound to the aggregates, the rest remaining in the fluid phase as inactive C4b. It has been found that C4b and th antibody form a very stable complex, due probably to the formation of a covalent bond. On reduction of the C4b-immunoglobulin G (IgG) complex, the beta and gamma chains, but not the alpha' chain, of C4b are released together with all the light chain, but only about half of the heavy chain of IgG. The reduced aggregates contain two main higher-molecular-weight complexes, one shown by the use of radioactive components to contain both IgG and C4b and probably therefore the alpha' chain of C4b and the heavy chain of IgG, and the other only C4b and probably an alpha' chain dimer. The aggregates with bound C1 and C4b show maximal C3 convertase activity, in the presence of excess C2, when the alpha'-H chain component is in relatively highest amounts. When C4 is incubated with C1s in the absence of aggregates, up to 15% of a C4b dimer is formed, which on reduction gives an alpha' chain complex, probably a dimer. The apparent covalent interaction between C4b and IgG and between C4b and other C4b molecules cannot be inhibited by iodoacetamide and hence cannot be catalysed by transglutaminase (factor XIII). The reaction is, however, inhibited by cadaverine and putrescine and 14C-labelled putrescine is incorporated into C4, again by a strong, probably covalent, bond. It is suggested that a reactive group, possibly an acyl group, is generated when C4 is activated by C1 and that this reactive group can react with IgG, with another C4 molecule, or with water.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6906229      PMCID: PMC1161918          DOI: 10.1042/bj1890067

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Interaction between the third complement protein and cell surface macromolecules.

Authors:  S K Law; R P Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

2.  Purification of human complement subcomponent C4. C4 cleavage by C1s.

Authors:  A Reboul; N Thielens; M B Villiers; M G Colomb
Journal:  FEBS Lett       Date:  1979-07-01       Impact factor: 4.124

3.  Titration and subunit localization of active center cysteine in fibrinoligase (thrombin-activated fibrin stabilizing fector).

Authors:  C G Curtis; P Stenberg; C H Chou; A Gray; K L Brown; L Lorand
Journal:  Biochem Biophys Res Commun       Date:  1973-05-01       Impact factor: 3.575

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  The assembly of early components of complement on antibody-antigen aggregates and on antibody-coated erythrocytes.

Authors:  J W Goers; R R Porter
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

6.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

7.  The reaction mechanism of human C5 in immune hemolysis.

Authors:  N R Cooper; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

8.  Limited proteolysis of complement components C2 and factor B. Structural analogy and limited sequence homology.

Authors:  M A Kerr
Journal:  Biochem J       Date:  1979-12-01       Impact factor: 3.857

9.  Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.

Authors:  H J Müller-Eberhard; M J Polley; M A Calcott
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

10.  ISOLATION AND DESCRIPTION OF THE FOURTH COMPONENT OF HUMAN COMPLEMENT.

Authors:  H J MUELLER-EBERHARD; C E BIRO
Journal:  J Exp Med       Date:  1963-09-01       Impact factor: 14.307

View more
  32 in total

1.  Solid phase enzyme linked immunosorbent assay for classical complement activation pathway.

Authors:  M Rhen
Journal:  J Clin Pathol       Date:  1987-02       Impact factor: 3.411

2.  Limulus alpha 2-macroglobulin. First evidence in an invertebrate for a protein containing an internal thiol ester bond.

Authors:  P B Armstrong; J P Quigley
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

3.  Common evolutionary origin of alpha 2-macroglobulin and complement components C3 and C4.

Authors:  L Sottrup-Jensen; T M Stepanik; T Kristensen; P B Lønblad; C M Jones; D M Wierzbicki; S Magnusson; H Domdey; R A Wetsel; A Lundwall
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

4.  C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.

Authors:  L C Antón; J M Alcolea; P Sánchez-Corral; G Marqués; A Sánchez; F Vivanco
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

5.  Sequence determination of the thiolester site of the fourth component of human complement.

Authors:  R A Harrison; M L Thomas; B F Tack
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

6.  Analysis of structural similarities between brain Thy-1 antigen and immunoglobulin domains. Evidence for an evolutionary relationship and a hypothesis for its functional significance.

Authors:  F E Cohen; J Novotný; M J Sternberg; D G Campbell; A F Williams
Journal:  Biochem J       Date:  1981-04-01       Impact factor: 3.857

7.  Amino acid sequence around the thiol and reactive acyl groups of human complement component C4.

Authors:  R D Campbell; J Gagnon; R R Porter
Journal:  Biochem J       Date:  1981-11-01       Impact factor: 3.857

8.  Human complement component C4. Structural studies on the fragments derived from C4b by cleavage with C3b inactivator.

Authors:  E M Press; J Gagnon
Journal:  Biochem J       Date:  1981-11-01       Impact factor: 3.857

9.  Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules.

Authors:  E J Brown; M Berger; K A Joiner; M M Frank
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

10.  The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.

Authors:  R G DiScipio
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.